Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF) is a leader in biofilm-disrupting technologies for advanced wound and scalp care. This page aggregates all official company announcements, providing stakeholders with timely updates on regulatory progress, product developments, and strategic initiatives.
Investors and industry professionals will find comprehensive coverage of FDA clearances, manufacturing partnerships, and global licensing agreements. Our curated news stream includes earnings reports, clinical advancements, and distribution expansions, ensuring you never miss critical developments affecting KNBIF's market position.
Key focus areas include updates about antimicrobial wound care solutions, scalp health innovations, and quality certifications like ISO 13485:2016. Bookmark this page for direct access to primary-source information about Kane Biotech's progress in combating biofilm-related health challenges worldwide.
Kane Biotech (TSX-V:KNE) has submitted a 510(k) clearance application to the FDA for its revyve® Antimicrobial Wound Cleanser. This marks the company's third product in the revyve line, complementing their existing Antimicrobial Wound Gel and Gel Spray products.
The new cleanser is designed for routine wound management, specifically for irrigating acute and chronic wounds to reduce bacterial load and remove loose material. The product's formulation is based on the existing revyve Antimicrobial Wound Gel. Notably, the U.S. wound cleanser market exceeded $200M USD in 2024.
Kane Biotech (OTCQB:KNBIF) has successfully completed enrollment for its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing its target with 28 participants versus the planned 25. The studies, involving wound care and burn specialists in the U.S., focus on the FDA 510(k) cleared revyve Antimicrobial Wound Gel.
The company plans to present the clinical data at various medical meetings throughout 2025 and 2026. According to Interim CEO Dr. Robert Huizinga, there has been encouraging interest from both clinicians and patients, with revyve products showing potential to significantly improve outcomes for patients with challenging wounds and burns.
Kane Biotech (KNBIF) announced that Interim CEO Dr. Robert Huizinga will present clinical data for their FDA 510(k) cleared revyve® products at the Symposium on Advanced Wound Care Fall conference in Las Vegas.
Two significant case studies will be presented: The first demonstrates how revyve Antimicrobial Wound Gel successfully treated a two-year-old Stage 4 sacral ulcer, reducing pain scores from 10/10 to 0 and decreasing wound size over three weeks. The second case study shows how the gel, combined with vibrational debridement, achieved a 60% wound size reduction over eight weeks in a two-year-old venous leg ulcer, with pain scores dropping from 5/10 to 0.
Kane Biotech (TSX-V:KNE) reported challenging Q2 2025 financial results, with revenue declining to $27,997 from $620,437 in Q2 2024, primarily due to the sale of its animal health business. The company posted a net loss of $(348,541), improved from $(1,215,996) in the previous year.
Key developments include the election of three new directors to the board, termination of the ProgenaCare distribution agreement, and conversion of a $1 million insider loan into a convertible debenture. The company faces challenges with a PrairiesCan default notice for approximately $1.4 million outstanding.
Kane continues to advance its wound care initiatives, presenting preclinical data at major conferences and conducting clinical case studies for its revyve® portfolio, while seeking new US distribution partners.
Kane Biotech (KNBIF) presented significant preclinical data and clinical case studies for its revyve™ Antimicrobial Wound Gel at two major North American wound care conferences. The preclinical in vitro studies demonstrated remarkable protease inhibition, including 80% reduction in MMP activity, 82% reduction in elastase activity, and 100% reduction in collagenase and TACE enzyme activity.
Clinical case studies showed meaningful improvements in chronic wound patients, including wound size reduction, pain elimination, and improved tissue regranulation over 6-12 weeks. Notable cases included a 60% wound size reduction in a venous leg ulcer over two months and significant improvements in pressure wound cases.
Kane Biotech (TSX-V: KNE) has announced that Interim CEO Dr. Robert Huizinga will present at the 4th Advanced Wound Care Summit USA in Boston, MA from July 15-17, 2025. The summit brings together industry leaders, innovators, payers, and regulators in the wound care sector to discuss transforming breakthrough science into accessible therapies.
Dr. Huizinga's presentation will be made available on Kane's website on July 16, 2025.
Kane Biotech reported its Q4 and full-year 2024 financial results, announcing a strategic shift and leadership change. Q4 revenue reached $125,859, up from $57,788 in Q4 2023, while full-year 2024 revenue increased to $2.08M compared to $148,980 in 2023.
The company is narrowing its focus to four key wound care products under its coactiv+™ biofilm technology:
- revyve™ Antimicrobial Wound Gel (FDA and Health Canada approved)
- revyve™ Antimicrobial Wound Gel Spray (FDA approved)
- coactiv+™ Antimicrobial Surgical Hydrogel (2026 approval target)
- revyve™ Antimicrobial Wound Rinse (2026 approval target)
In leadership changes, Marc Edwards departed as CEO, replaced by interim CEO Dr. Robert Huizinga. The company secured $2.2M in funding through insider investments: $1.2M via private placement at $0.10 per share and a $1M unsecured loan. Cost reduction initiatives have been implemented, including reduced focus on DispersinB® development.
Kane Biotech (KNBIF) has received Internal Review Board (IRB) approval from the University of Miami Health System to begin a clinical study of their DispersinB® Acne Cleanser for treating mild to moderate Acne Vulgaris.
The study, titled 'Split-face efficacy and tolerability of DispersinB® Acne Cleanser in the treatment of mild to moderate Acne Vulgaris,' will be conducted at the University of Miami Miller School of Medicine. The trial is scheduled to commence by mid-2025 and will involve up to 24 subjects.
The research will take place at the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, which is recognized as a global leader in skin condition treatments.
FAQ
What is the current stock price of Kane Biotech (KNBIF)?
What is the market cap of Kane Biotech (KNBIF)?
